Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

por Solms, Alexander, Frede, Matthias, Berkowitz, Scott D., Hermanowski‐Vosatka, Anne, Kubitza, Dagmar, Mueck, Wolfgang, Spiro, Theodore E., Willmann, Stefan, Yan, Xiaoyu, Zhang, Liping, Garmann, Dirk
Publicado 2019

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

por Zhang, Liping, Yan, Xiaoyu, Nandy, Partha, Willmann, Stefan, Fox, Keith A. A., Berkowitz, Scott D., Sharma, Amarnath, Hermanowski-Vosatka, Anne, Schmidt, Stephan, Weitz, Jeffrey I., Garmann, Dirk, Peters, Gary
Publicado 2019

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation

por Zhang, Liping, Yan, Xiaoyu, Fox, Keith A. A., Willmann, Stefan, Nandy, Partha, Berkowitz, Scott D., Hermanowski-Vosatka, Anne, Weitz, Jeffrey I., Solms, Alexander, Schmidt, Stephan, Patel, Manesh, Peters, Gary
Publicado 2020

Infectious Agents Are Not Necessary for Murine Atherogenesis

por Wright, Samuel D., Burton, Charlotte, Hernandez, Melba, Hassing, Heide, Montenegro, Judy, Mundt, Steve, Patel, Sushma, Card, Deborah J., Hermanowski-Vosatka, Anne, Bergstrom, James D., Sparrow, Carl P., Detmers, Patricia A., Chao, Yu-Sheng
Publicado 2000

11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

por Hermanowski-Vosatka, Anne, Balkovec, James M., Cheng, Kang, Chen, Howard Y., Hernandez, Melba, Koo, Gloria C., Le Grand, Cheryl B., Li, Zhihua, Metzger, Joseph M., Mundt, Steven S., Noonan, Heather, Nunes, Christian N., Olson, Steven H., Pikounis, Bill, Ren, Ning, Robertson, Nancy, Schaeffer, James M., Shah, Kashmira, Springer, Martin S., Strack, Alison M., Strowski, Matthias, Wu, Kenneth, Wu, TsueiJu, Xiao, Jianying, Zhang, Bei B., Wright, Samuel D., Thieringer, Rolf
Publicado 2005